Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 6/20 | 0.42 |
| ▸ | DDB1 | Q16531 | 5/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30688284 | 1.00 | GPR119 (0.43) | GPR119CRBNDDB1KDM4ENPC1 | |
| SCHEMBL29507093 | 0.88 | GPR119 (0.50) | GPR119CRBNDDB1 | |
| SCHEMBL25430509 | 0.88 | GPR119 (0.50) | GPR119CRBNDDB1 | |
| SCHEMBL26683989 | 0.86 | MGLL (0.44) | GPR119CRBNDDB1 | |
| SCHEMBL29506992 | 0.82 | GPR119 (0.47) | GPR119CRBNDDB1SMN1; SMN2 | |
| SCHEMBL25337718 | 0.82 | GPR119 (0.47) | GPR119CRBNDDB1SMN1; SMN2 | |
| SCHEMBL30688300 | 0.81 | DDB1 (0.40) | GPR119CRBNDDB1SMN1; SMN2 | |
| SCHEMBL26683550 | 0.81 | DDB1 (0.40) | GPR119CRBNDDB1SMN1; SMN2 | |
| SCHEMBL26684253 | 0.76 | GPR119 (0.40) | GPR119CRBNDDB1KDM4ENPC1 | |
| SCHEMBL30688293 | 0.76 | DDB1 (0.42) | CRBNDDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230374007-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2023-11-23 | — | — | US | disclosed |
| US-20230374007-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2023-11-23 | — | — | US | disclosed |
| US-20230374007-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2023-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230374007-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | RARA, RARG, RARB | GPR119 2044/4885CRBN 2312/4885DDB1 4162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.